Key PointsEli Lilly is a market darling because it is a leader in the GLP-1 weight-loss market.Pfizer hasn't even entered the GLP-1 race yet, which is one reason why its shares are comparatively unloved. But Pfizer's 6.6% yield is dramatically higher than Eli Lilly's 0.6%, which should make Pfizer enticing to dividend lovers.10 stocks we like better than Pfizer › Eli Lilly (NYSE: LLY) is basically hitting it out of the park right now. Sales of i…